Please use this identifier to cite or link to this item: https://scholarbank.nus.edu.sg/handle/10635/121862
Title: HEALTH ECONOMICS OF PHARMACOGENETIC TESTING
Authors: DONG DI
Keywords: Health Economics, Medical Decision Making, Genetic Testing, Adverse Drug Reactions, Pharmacogenetics, Health Policy
Issue Date: 11-Aug-2015
Citation: DONG DI (2015-08-11). HEALTH ECONOMICS OF PHARMACOGENETIC TESTING. ScholarBank@NUS Repository.
Abstract: SOME COMMONLY USED MEDICATIONS CAN CAUSE A LIFE-THREATENING ADVERSE DRUG REACTION NAMED STEVENS-JOHNSON SYNDROME (SJS). THOUGH THE GENETIC RISK FACTORS HAVE BEEN WELL ESTABLISHED, ADOPTION OF PHARMACOGENETIC TESTING TO REDUCE SJS RISK IN CLINICAL CARE HAS BEEN SLOW. I CONDUCT HEALTH ECONOMIC EVALUATIONS TO INFORM CLINICAL AND REGULATORY DECISION MAKING ON WHETHER PHARMACOGENETIC TESTING SHOULD BE DONE TO REDUCE THE RISK OF SJS IN SINGAPORE. I FIRST ASSESSED THE COST-EFFECTIVENESS OF TWO PHARMACOGENETIC TESTS FROM A HEALTH SYSTEM PERSPECTIVE, AND FOUND THAT GENOTYPING EPILEPSY PATIENTS FOR HLA-B*1502 PRIOR TO CARBAMAZEPINE TREATMENT WAS HIGHLY COST-EFFECTIVE, WHEREAS GENOTYPING CHRONIC GOUT PATIENTS FOR HLA-B*5801 PRIOR TO ALLOPURINOL TREATMENT WAS NOT COST-EFFECTIVE IN SINGAPORE. I THEN MEASURED PATIENTS? PREFERENCES FOR PHARMACOGENETIC TESTING IN CHRONIC GOUT TREATMENT. RESULTS SUGGESTED THAT RISK OF SJS, COST OF GENOTYPING, COST OF GOUT TREATMENT, DOCTOR?S RECOMMENDATION AND CHOICE
URI: http://scholarbank.nus.edu.sg/handle/10635/121862
Appears in Collections:Ph.D Theses (Open)

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Dong Di Dissertation.pdf3.65 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.